The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial.
Phil McEwanAngharad R MorganRebecca BoyceKlas BergenheimIngrid A M Gause-NilssonDeepak L BhattLawrence Alan LeiterPeter A JohanssonLawrence A LeiterAvivit CahnJohn P H WildingPublished in: Diabetes, obesity & metabolism (2021)
The results of this study demonstrate that dapagliflozin compared to placebo appears to be cost-effective, when considering evidence reported from the DECLARE-TIMI 58 trial, at established UK willingness-to-pay thresholds. The findings highlight the potential of dapagliflozin to have a meaningful impact in reducing the economic burden of T2DM and its associated complications across a broad T2DM population.